Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
A recombinant Fab neutralizes dengue virus in vitro

P. Thullier a,b, P. Lafaye a,*, F. Mégret c, V. Deubel c, A. Jouan b, J.C. Mazié a

a Laboratoire d’Ingénierie des Anticorps, Institut Pasteur, 25 rue du Dr Roux, 75724 Paris Cedex 15, France
b Département de Biologie des Agents Transmissibles, Centre de recherche du Service de Santé des Armées, La Tronche, France
c Unité des Arbovirus et Virus des Fièvres Hémorragiques, Institut Pasteur, Paris, France

Received 25 August 1998; received in revised form 14 January 1999; accepted 27 January 1999

Abstract

A recombinant Fab that recognizes a neutralizing epitope located in the (296–400) region of protein E of dengue virus was obtained from cloned hybridoma cells secreting the mouse monoclonal antibody (mAb) 4E11. The Fd and light chain antibody genes were amplified by polymerase chain reaction, cloned into the phagemid vector pMad, expressed in bacteria to produce Fab fragments and sequenced. The mAb 4E11, in particular its light chain complementary-determining regions, shared homologies with two other anti-viral mAbs. The affinity of the parental mAb and the cloned Fab to the MalE-E(296–400) fusion protein were shown to be of the same magnitude, i.e. nanomolar. Fab 4E11 neutralization capacity was found between 8 and 4-times or less lower than that of mAb 4E11, depending on serotypes, thus the Fab could have a smaller antiviral activity than the mAb in vitro. © 1999 Elsevier Science B.V. All rights reserved.

Keywords: Fab; Recombinant; Dengue; Neutralization; Phages

1. Introduction

Dengue virus is a member of the Flaviviridae family. This virus causes a disease prevalent between 30th north and 20th south parallels and its incidence has been estimated to 60 million per year, causing 30 000 deaths (Tolou et al., 1997), with appearance of hyper endemic transmission in the Americas (Gubler, 1998). It is transmitted among humans by mosquitoes, mainly Aedes aegypti.

A wide spectrum of symptoms can be encountered, ranging from a benign fever with occasional hemorrhages to a potentially fatal syndrome. Without medical intervention, the case fatality rate of the hemorrhagic and shock syndrome can reach 40–50% (Igarashi, 1997). The mechanisms of this syndrome are still under discussion: (i) specific strains could be involved (Murgue et al.,

* Corresponding author. Fax: +33-145-688790.
E-mail address: plafaye@pasteur.fr (P. Lafaye)
and (ii) preexisting subneutralizing antibodies could enhance the antibody-mediated uptake of the virus by monocytes or macrophages which are designated as host cells of the virus (antibody dependent enhancement: ADE) (Hawkes and Lafferty, 1967; see review in Porterfield, 1986). The requirement for the Fc region of IgG in ADE has been demonstrated by Halstead and O'Rourke (1977) who compared whole human serum, that had enhancing activity and Fab2 of the same origin that had not. The requirement for functional Fcγ receptors in ADE has also been shown (Littaua et al., 1996). These receptors, present at the surface of macrophages, play a major role in the phagocytosis of antibody-coated particles (Paul, 1993) and are dependent on the Fc binding of IgG.

No specific prophylactic or therapeutic agent is currently available against dengue disease. Intravenous infusion to correct hypovolemia and eventually blood transfusion, can reduce the mortality rate. Monoclonal antibodies passively transferred to mice challenged with a lethal intracerebral dose of dengue 2 virus have been shown to be protective (Kaufman et al., 1987). In the case of another virus (vesicular stomatitis virus) protection against lethal infection has been shown to be mediated by neutralizing antibodies (Zinkernagel, 1997). Immunotherapy of dengue, as prophylaxis or treatment, could thus be of interest. IgG fragments lacking Fc (scFv or Fab) should be used so that they do not participate in any enhancing effects (ADE). For this work, Fab were prefered to scFv because they have a better stability, resulting in a longer half-life. A Fab has recently been shown to have a 55-fold greater half-life than its corresponding scFv (Lamarre et al., 1997).

In this study, we have cloned in a phagemidic vector the Fab region of the murine monoclonal antibody (mAb) 4E11, raised against dengue virus. Immunochemical and serological properties of the mAb and the Fab were compared.

2. Materials and methods

2.1. Preparation and characterization of the hybridoma

Hybridoma cells producing a murine monoclonal antibody 4E11, recognizing dengue virus, serotype 1 envelope protein, were prepared according to protocols published previously (Morens et al., 1987). These cells were a generous gift from Dr D.M. Morens. The mAb is of the IgG2a, k, isotype and is protective in vivo against dengue virus, serotype 1: 0.4 mg protected all 3 weeks-old BALB/c mice challenged with 100 DL50 (data not shown).

2.2. Production of phage-displayed Fab fragments

Total RNAs were isolated from 5 × 10⁶ cells of the mouse 4E11 hybridoma (RNAxel®, Eurobio, Les Ulis, France). cDNA was synthesized using random hexanucleotides (Lafaye et al., 1995) and MLV enzyme (Eurobio), then PCR-amplified (Saiki et al., 1985). The PCR primers harboured a restriction site that enabled the double-stranded PCR products to be cloned into the vector. The 5′ primers were designed to hybridize to partially conserved sequences coding for the N-terminus of variable regions. Four 5′ primers for light chain and eight 5′ primers for Fd had to be tested, depending on the family to which belonged the template. The 3′ primers hybridize in the region corresponding to the light chain C-terminus and to the hinge region of Fd (Kang et al., 1991). PCR conditions were described elsewhere (Lafaye et al., 1995). After digestion by SacI and XbaI (Gibco, Gaithersburg, MD), the light chain gene was cloned into the phagemidic expression vector pMad (kindly given to us by...
G. Orfanoudakis, E.S.B.S., Strasbourg). After digestion with XhoI and SpeI (Boehringer, Mannheim, Germany), the Fd gene was cloned in frame with the gene for minor coat protein III (PIII) of filamentous phages, in the vector having already received the light chain gene (for a schematic drawing of the construct, see Barbas et al., 1991).

2.3. E. coli expression and purification of phages-Fab

The phagemid was then introduced into competent E. coli cells by CaCl₂ transformation (Sambrook et al., 1989) at an efficiency rate of $2 \times 10^5$ transformants per mg phagemid. The phage-Fab was obtained as described elsewhere (Lafaye et al., 1995), then it was titrated (Parmley and Smith, 1988) and analysed by ELISA, as described below.

2.4. Production of Fab fragments

The selected phagemid was digested with NheI and SpeI (Boehringer) to remove the gene coding for PIII, then ligated and transformed (Barbas et al., 1991). This clone was cultivated in 2YT/ampicillin at 37°C until a OD₆₀₀ of 1.8 was reached. IPTG was added at a concentration of 1 mM and the culture was grown overnight at 30°C, with stirring. Cells were pelleted by centrifugation and soluble Fab were recovered from the periplasm by osmotic shock. One ml of buffer (8.6 g saccharose, 100 µl EDTA 0.5M pH 8.0, 10 ml Tris 1 M pH 8.0, milli-Q purified water for a total volume of 50 ml) was used for the extraction of Fab expressed in 70 ml culture. The periplasmic fraction was cleared by centrifugation (10 000 × g, 4°C, 20 min) and Fab were purified with an affinity column prepared by covalently coupling anti-mouse Fab antibodies (Sigma, St. Louis, MO) to protein G-sepharose 4B (Sigma) with 20 mM dimethylpimelimidate (Sigma) (Harlow and Lane, 1988). The Fab were eluted with 100 mM glycine pH 2.5, neutralized by adding 3M Tris–HCl pH 9.0, dialysed against PBS and filtered (Millex-GP 0.22 µm, Millipore, Bedford, MA).

2.5. ELISA

A protein E fragment of dengue virus, strain FGA/89 (Despres et al., 1993), located between residues 296 and 400 (E(296–400)), was cloned as a MalE fusion protein in p-MALc plasmid (Biolabs, Beverly, MA) following the procedure described previously (Megret et al., 1992). The protein was produced in E. coli and purified on a maltodextrin column according to the manufacturer procedures (Biolabs). This protein at a concentration of 1 µg ml⁻¹ in PBS was coated for 2 h at 37°C on microtiter plates (Nunc, Roskilde, Denmark). Plates were washed six times in PBS/0.5% gelatin/0.1% Tween (PGT), then non specific binding was blocked for 1 h at 37°C with PGT. Two-fold dilutions of 100 µl of phage-Fab, starting with 10¹² Transforming Units per ml were distributed in the wells. The negative control was a non recombinant phage. After 2 h at 37°C, plates were washed and each well was incubated with 100 µl of an anti-phage M13 horse radish peroxidase (HRP) conjugate (Pharmacia, Uppsala, Sweden) and revealed with orthophenylene-diamine dihydrochloride (Dako, Glostrup, Denmark). The 490 nm absorbance was measured on an ELISA reader (Dynatech, Guernsey). Concentration of soluble Fab in periplasmic extract were ELISA assayed using a rat anti-mouse chain (Immunochem, Marseille, France) that was coated and a goat anti-mouse Fab HRP conjugate (Sigma) for revelation. The result was established by comparison with the purified recombinant Fab.

2.6. Affinity measurements

Affinity was measured in solution (Friguet et al., 1985). Samples of Fab 4E11 (as periplasmic extract diluted 1/640 in PGT) or mAb 4E11 (5 ng ml⁻¹) were incubated overnight with increasing amounts of MalE-E(296–400), at concentrations ranging from 10⁻¹¹ to 10⁻⁷ M. The remaining free antigen-binding sites were then quantified by ELISA, using an anti-mouse β-galactosidase conjugate (J. Gregoire, Pasteur Institute, Paris) and 4-methylumbelliferyl β-D galactoside (Sigma). Fluorescence was read (Fluoroskan,
Labsystem, Finland) at 460 nm, after excitation at 355 nm.

2.7. Sequencing, analysis and modeling of the Fab-DNA fragment

Automatized sequencing was performed by Genome Express S.A. (Grenoble, France), using P13 (5’ GCC GCT GGA TTG TTA TTA CTC 3’) and P21 (5’ CAC CCT CAG AGC CAC CCT 3’) for Fd sequencing and KEF (5’ GAA TTC TAA ACT AGC TAG TCG 3’) and Universal Primer (5’ TGA CCG GCA GCA AAA TG 3’) for light chain sequencing.

The DNA sequences in the Genbank/EMBL nucleotide sequence data base were compared using Genetics Computer Group software (University of Wisconsin, WI). The DNA sequences of the Fab heavy and light chains are accessible in Genbank under the following numbers, respectively, AJ131288 and AJ131289.

2.8. Plaque-reduction neutralization tests

Neutralization tests were performed on Vero cells, in 24-wells culture plates with prototype dengue viruses of the four serotypes. Dengue virus strains were the following: Hawaii 1944 for serotype 1, New Guinea C 1944 for serotype 2, H 87 for serotype 3, H 241 for serotype 4. Periplasmic extract containing Fab 4E11, periplasmic extract of non-transformed TG1, purified Fab 4E11 (all stored at 20°C) and parental mAb (stored at high concentration at 4°C) were incubated in two-fold serial dilutions with 100 Focus Forming Units (FFU) of virus overnight at 4°C (Desprès et al., 1993). The mixture was then incubated, in duplicate, on Vero cells for 2 h at 37°C with Isocarboxycellulose 1.6% and then re-incubated at 37°C in a 5% CO₂ incubator during 5 days for serotypes 2 and 4 and 6 days for serotypes 1 and 3. After fixation, plaques were revealed with anti-dengue virus specific hyperimmunized mouse ascitic fluids, then with an anti-mouse HRP conjugate. The neutralization capacity was estimated as the mAb or Fab concentration causing 50% reduction of FFU.

3. Results and discussion

In this work, starting with the murine hybridoma 4E11, we have prepared a recombinant Fab and compared its properties with those of the parental mAb.

3.1. Isolation of Fab cDNA

mRNA was extracted from a culture of hybridoma cells 4E11 and utilized as a template for RT-PCR to obtain cDNA. The 3’ primer CkDNA and the 5’ primer LC7 allowed the amplification of a DNA fragment of a length of 650 bp, which is the size for a DNA fragment coding for a light chain. The 3’ primer IgG2a and the 5’ primer VH1IC allowed the amplification of DNA coding for Fd. The DNA fragment coding for the light chain was inserted first in the pMad phagemidic vector and then the fragment coding for the heavy chain.

One clone constructed with the light chain and Fd genes from 4E11 was ELISA tested for binding to MalE-E(296–400) fusion protein and compared to a phage having incorporated no heterologous gene. The signal obtained with the phage-Fab was constantly above the negative phage and linearly dependent on the phage-Fab concentration (data not shown). For soluble Fab production, the gene coding for minor coat protein III was removed by NheI and SpeI digestion.

3.2. DNA sequence analysis

When compared to the data base, Fd belonged to the VH14 family consisting of four members: X62705 (Moncharmont et al., 1982) with which most identity (90%) was shared, X07144 (Rocca-Serra et al., 1983), M13068 (Roth et al., 1985) and Z22138 (Tillman et al., 1992). These antibodies were directed against an oestrogen receptor (X62705), against an hapten (GAT) (X07144 and M13068) and against DNA (Z22138). The D segment of Fd corresponded to the DQ52 genetic element and the junction segment corresponded to the JH3 genetic element.
The sequence of the light chain of 4E11 belonged to the VK 21 group III subgroup. When compared with sequences of other light chain coding genes, two of the three genes presenting most homologies were from anti-viral IgG. The non anti-viral IgG was directed against CD 18 (95.2% identity). The anti-viral IgG were directed against influenza virus (X59209, Stark and Caton, 1991) (96% identity) and Hantaan virus (L46814, Liang et al., 1996) (95.2% identity); the identity between CDRs being 77 and 95%, respectively. Because the third light chain CDR (L3) plays a significant role in antigen recognition, the conservation of six of its nine residues is noteworthy. Identities between the Fd of these IgG were less remarkable, though 40% of the CDR 2 (H2) was identical.

The fine mapping of 4E11 epitope could provide clues to test the hypothesis that the use of variants of this light chain among three antiviral antibodies could eventually signal the presence of comparable epitopes at the surface of the three different viruses.

3.3. Immunochemical and serological properties

3.3.1. Affinity measurements

The affinity of the mAb and the Fab for MalE-E(296–400) binding were, respectively, measured as $3.77 \times 10^{-9}$ and $1.7 \times 10^{-9}$ M and can be considered as equivalent due to experimental variations and precision of the method.

3.3.2. Quantification and purification of the soluble Fab

The Fab was harvested in periplasmic extract, purified and electrophoresed on a 10% SDS-PAGE gel. Two narrowly separated bands of approximately 25 kD were shown, corresponding to light chain and Fd present in similar quantities (Fig. 1). No contaminant was present and the concentration was measured as 9 μg ml$^{-1}$ by Bradford’s method.

![Figure 1: Coomassie stained 10% SDS PAGE gel of Fab 4E11. The two narrowly separated bands of an approximate apparent molecular weight of 25 kD correspond to the light chain and Fd.](image-url)
Table 1
Plaque reduction neutralization test of 4E11 against the four serotypes of dengue virus

| Dengue virus | mAb 4E11 (µg ml⁻¹) | Fab 4E11 (purified form) (µg ml⁻¹) | Fab 4E11 (in periplasmic extract) (µg ml⁻¹) |
|--------------|---------------------|-----------------------------------|--------------------------------------------|
| Serotype 1   | 0.28                | 2.25                              | 2.25                                       |
| Serotype 2   | 2.25                | ND                                | 18                                         |
| Serotype 3   | 2.25                | 9                                 | 9                                          |
| Serotype 4   | >2.25               | ND                                | 18                                         |

*Titers are shown as the concentration of mAb or Fab giving a 50% reduction in the number of FFU. Such a titer could not be determined (ND) utilizing purified Fab 4E11 against serotypes 2 and 4, because the concentration of this preparation (9 µg ml⁻¹) was too low.

3.3.3. PRNT

PRNT (50% inhibition) were performed for the four serotypes during the same experiment in order to allow comparisons to be made between Fab (purified Fab and Fab in periplasmic extract) and mAb and between serotypes. This experiment was preceded by preliminary experiments, whose results are in accordance with those given in Table 1 (data not shown). mAb concentration which neutralized serotype 1 (0.28 µg ml⁻¹) (Fig. 2) was lower than that neutralizing serotypes 2 and 3 (2.25 µg ml⁻¹) and serotype 4 (>2.25 µg ml⁻¹) (Table 1). Periplasmic extract without Fab did not show any neutralizing properties. Fab neutralization capacity could be estimated as 8 times (serotypes 1 and 2) to four times (serotype 3) and four times or less (serotype 4) lower than that of mAb 4E11.

Despite experimental variations observed between the tested serotypes, some reduction of Fab neutralizing capacity when compared with the parental mAb was observed. It has already been reported that neutralization by a Fab is usually reduced by at least one order of magnitude compared with its parental IgG (Schofield et al., 1997), but the observed reduction was not in agreement with the conserved affinity. Technical reasons for this apparent loss of activity, such as alterations during freeze-thaw, or defects in the association of the light chain and Fd could not be ruled out despite the taken precautions. These reasons would not have hampered the affinity measurements, which were not dependent on the quantity of active Fab present in the tested solution, but only on the linearity of the signal with respect to the dilution. Reasons based on the mechanism of neutralization could also be proposed. Because Fab 4E11 bound to the envelope protein of the virus, it should block the attachment of the virus to the host cell, by binding close to the attachment site (see review in Dimmock, 1993). This blocking could be less complete by the Fab than by the Mab, due to reduction in Fab steric hindrance. Because no effector for Fc is present in the in vitro neutralization essay, the fact that the lack of Fc seems to cause a reduction of neutralization properties can be mostly explained by this reduction of Fab steric hindrance.

Our in vitro neutralization experiments by recombinant Fab 4E11 proved that Fc and diva-

![Fig. 2. PRNT of dengue 1 virus by periplasmic extract containing Fab 4E11, purified Fab 4E11 and purified mAb 4E11 diluted 2-fold. Initial concentrations (C1) are indicated. Tests were realized in duplicate.](image-url)
lence of the parental mAb were not necessary to the neutralization process. Such results have already been established by Fab obtained by papain digestion, but could be subject to caution due to incomplete digestion (Dimmock, 1993). These results cannot be generalised to all monoclonal antibodies (Ubol et al., 1995).

In a medical perspective, more work could be done to improve the production of Fab 4E11 and to test it in vivo. The humanization of Fab 4E11, or the search for an antibody of similar properties but of human origin, that would be better tolerated in medical use, can also be pursued. Recent availability for medical practice of a recombinant mouse-human chimera Fab (Abciximab® used as an anti-aggregant) gives ground for hope that long-pursued antiviral seroprophylaxis or serotherapy may some day become reality.

Acknowledgements

Hybridoma cells were a generous gift from Dr D.M. Morens and the phagemidic vector pMad was granted to us by Dr Orfanoudakis. We want to thank M.T. Drouet for her technical skills in the realization of PRNT and Dr P. England for enlightened discussions. This work was supported by a grant from D.R.E.T (contrat n° 97 2518A).

References

Barbas, C.F., Kang, A.S., Lerner, R.A., Benkovic, S.T., 1991. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc. Natl. Acad. Sci. USA 88, 7978–7982.

Barbas, C., Crowe, J., Cababa, D., Jones, T., Zebedee, S.L., Murphy, B.R., Chanock, R.M., Burton, D.R., 1992. Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncitial virus F glycoprotein and neutralise infectivity. Proc. Natl. Acad. Sci. USA 89, 10164–10168.

Burton, D.R., Barbas, C., Persson, M.A., Koenig, S., Chanock, R.M., Lerner, R.A., 1991. A large array of human monoclonal antibodies to type I human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88, 10134–10137.

Caton, A.J., Koprowski, H., 1990. Influenza virus hemagglutinin-specific antibodies isolated from a combinatorial expression library are closely related to the immune response of the donor. Proc. Natl. Acad. Sci. USA 87, 6450–6454.

Cheung, S.C., Dietzchold, B., Koprowski, H., Notking, A.L., Rando, R.F., 1992. A recombinant human Fab expressed in Escherichia coli neutralizes rabies virus. J. Virol. 66, 6714–6720.

Després, P., Frenkel, M.P., Deubel, V., 1993. Differences between cell membrane fusion activities of two dengue type-1 isolates reflect modifications of viral structure. Virology 196 (1), 209–219.

Dimmock, N.J., 1993. Neutralization by fragments of antibody. In: Capron, A., Compans, W., Cooper, M., Koprowski, H., McConnoll, I., Melchers, F., Oldstone, M., Olsnes, S., Poter, M., Saedler, H., Vogt, P.K., Wagner, H, Wilson, I. (Eds.), Neutralization of Animal Viruses. Springer, Berlin, pp. 67–70.

Friguet, B., Djavadi-Ohaniance, L., Bussard, A., Goldberg, M.E., 1985. Measurement of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J. Immunol. Methods 77, 305–319.

Gubler, D.J., 1998. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11 (3), 480–496.

Halstead, S.B., O’Rourke, E.J., 1977. Dengue viruses and mononuclear phagocytes. J. Exp. Med. 146, 201–217.

Harlow, E., Lane, D., 1988. Antibodies, A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor.

Hawkes, R.A., Lafferty, K.J., 1967. The enhancement of virus infectivity by antibody. Virology 33, 250–261.

Igarashi, A., 1997. Impact of dengue virus infection and its control. FEMS 18, 291–300.

Jiang, W.R., Lowe, A., Higgs, S., Reid, H., Gould, E.A., 1993. Single amino acid codon changes detected in louping ill virus antibody-resistant mutants with reduced neurovirulence. J. Gen. Virol 74, 931–935.

Kang, A.S., Burton, D.R., Lerner, R.A., 1991. Combinatorial immunoglobulin libraries in phage λ. Methods: a companion to Methods Enzymol. 2 (2) 111–118.

Kaufman, B.M., Summers, P.L., Dubois, D.R., Eckels, K.H., 1987. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 36 (2), 427–434.

Lafaye, P., Nato, F., Mazzié, J.-C., Doyen, N., 1995. Similar binding properties for a neutralizing anti-tetanus toxoid human monoclonal antibody and its bacterially expressed Fab. Res. Immunol. 146, 373–382.

Lamarre, A., Talbot, P.J., 1995. Protection from lethal coronavirus infection by immunoglobulin fragments. J. Immunol. 154, 3975–3984.

Lamarre, A., Yu, M.W.N., Chagnon, F., Talbot, P.J., 1997. A recombinant single chain antibody neutralizes coronavirus infectivity but only slightly delays lethal infection of mice. Eur. J. Immunol. 27, 3447–3455.

Liang, M., Chu, Y.-K., Schmaljohn, C., 1996. Bacterial expression of neutralizing mouse monoclonal antibody Fab fragments to Hantaan virus. Virology 217, 262–271.
Littaua, R., Karane, I., Ennis, F.A., 1996. Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J. Immunol. 144, 3183–3186.

Megret, F., Huckot, J.P., Falconar, A., Gentry, M.K., Morens, D.M., Murray, J.M., Schlesinger, J.J., Wright, P.J., Young, P., Van Regenmortel, M.H., 1992. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue envelope glycoprotein. Virology 187 (2), 480–491.

Moncharmont, B., Su, J.L., Parikh, I., 1982. Monoclonal antibodies against estrogen receptor: interaction with different molecular forms and functions of the receptor. Biochemistry 21 (26), 6916–6921.

Morens, D.M., Venkateshan, C.N., Halstead, S.B., 1987. Dengue 4 virus monoclonal antibodies identify epitopes that mediate immune infection enhancement of dengue 2 viruses. J. Gen. Virol. 68, 91–98.

Muller, B.H., Lafay, F., Demangel, C., Perrin, P., Tordo, N., Flamand, A., Lafaye, P., Guesdon, J.L., 1997. Both phage-displayed and soluble mouse scFv fragments neutralize rabies virus. J. Virol. Meth. 67 (2), 221–233.

Murgue, B., Cassar, O., Guignon, M., Chungue, E., 1997. Dengue virus inhibits human hematopoietic progenitor growth in vitro. J. Infect. Dis. 175 (6), 1497–1501.

Parmley, S.F., Smith, G.P., 1988. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 73, 305–318.

Paul, W.E., 1993. Fundamental Immunology, 3. Raven Press, New York.

Porterfield, J.S., 1986. Antibody-dependent enhancement of viral infectivity. Adv. Vir. Res. 31, 335–355.

Rocca-Serra, J., Mattthes, H.W., Kaartinen, M., Milstein, C., Theze, J., Fougeron, M., 1983. Analysis of antibody diversity: V-D-J mRNA nucleotide sequence of four anti-GAT monoclonal antibodies. A paucigene system using alternate D-J recombinations to generate functionally similar hypervariable regions. EMBO J. 2 (6), 867–872.

Roth, C., Rocca-Serra, J., Somme, G., Fougeron, M., Theze, J., 1985. Gene repertoire of the anti-poly (Glu-60 Ala-30 Tyr-10) (GAT) immune response: comparison of V-H, V-kappa and D regions used by anti-GAT antibodies and monoclonal antibodies produced after anti-idiotypic immunisation. Proc. Natl. Acad. Sci. USA 82, 4788–4792.

Saiki, R.K., Scharf, S., Faloona, F., Mullis, K.B., Horn, G., Erlich, H.A., Arnheim, N., 1985. Enzymatic amplification of β-globulin genomic sequences and restriction site analysis for diagnostic of sickle cell anemia. Science 230, 1350–1354.

Sambrook, J., Fritsch, E.F., Maniatis, T., 1989. Molecular cloning, 2. Cold Spring Harbor Laboratory Press, Cold Spring Harbor.

Schroeder, D.J., Stephenson, J.R., Dimmock, N.J., 1997. Variations in the neutralizing and haemagglutination-inhibiting activities of five influenza A virus-specific IgGs and their antibody fragment. J. Gen. Virol. 78, 2431–2439.

Stark, S.E., Caton, A.J., 1991. Antibodies that are specific for a single amino acid interchange in a protein epitope use structurally distinct variable regions. J. Exp. Med. 174, 613–624.

Tempest, P.R., Brenner, P., Lambert, M., Taylor, G., Furze, J.M., Carr, F.J., Harris, W.J., 1991. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnology 9, 266–271.

Tillman, D.M., Jou, N.T., Hill, R.J., Marion, T.N., 1992. Both IgM and IgG anti-DNA antibodies are the products of clonally selective B-cell stimulation in (NZB × NZW)F1 mice. J. Exp. Med. 176 (3), 761–779.

Tolou, H., Durand, J.P., Pisano, M.-R., 1997. Actualité de la dengue. Med. Trop. 57, 708–738.

Ubol, S., Levine, B., Swu-Hua, L., Greenspan, N.S., Griffin, D.E., 1995. Roles of immunoglobulin valency and the heavy-chain constant domain in antibody-mediated down-regulation of Sindbis virus replication in persistently infected neurons. J. Virol. 69 (3), 1990–1993.

Zebedee, S.L., Barbas, C.F., Hom, Y.L., Caotien, R.H., Graff, R., De Graw, J., Pyati, J., La Polla, R., Burton, D.R., Lerner, R.A., 1992. Human combinatorial antibody libraries to hepatitis B surface antigen. Proc. Natl. Acad. Sci. USA 89, 3175–3179.

Zinkernagel, R.M., 1997. Protective antibody responses against viruses. Biol. Chem. 378, 725–729.